Page 8 - Software Precertification Pilot Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Pear Therapeutics Announces Publication of Economic Analysis Assessing the Cost-Effectiveness of reSET-O® in Treating Opioid Use Disorder (OUD)
By
Staff
4 months ago
reSET-O® is the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for patients with opioid use disorder (OUD).
New economic analysis showed reSET-O to be cost-effective compared to treatment-as-usual alone over 12 weeks, and to have economic dominance when contingency management (CM) was included as part of treatment as usual.
BOSTON & SAN FRANCISCO–(BUSINESS WIRE)–Pear Therapeutics, Inc., today announced publication of a new economic analysis describing the cost-effectiveness of reSET-O®, the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for the treatment of opioid use disorder (OUD). The analysis, “ ....

United States , Corey Mccann , Keely Boyer , Hilaryf Luderer , Ba Fulton Velez , Stephen Braun , Karren Williams , Robert Gerwien , Sam Colman , Yuria Maricich , Charles Ruetsch Kathryn Anastassopoulos , Bruce Imbert , Laura Kauffman , Xiaorui Xiong , Fultonf Velez , Alice Kuo , Journal Of Current Medical Research , Council Of Economic Advisers , Expert Review Of Pharmacoeconomics Outcomes Research , Pear Therapeutics Inc , Food Drug Administration , Software Precertification Pilot Program , Prescription Digital Therapeutic , Pear Therapeutics , Medical Economics , Opioid Use Disorder ,